High-purity alpha-emitting isotope for Targeted Alpha Therapy — Actinium-225 supplied from Oak Ridge National Laboratory.
Actinium-225 (Ac-225), produced by Oak Ridge National Laboratory (ORNL), is a high-energy alpha-emitting radionuclide recognized as one of the most promising isotopes for Targeted Alpha Therapy (TAT).
With a half-life of approximately 10 days, Ac-225 decays through a chain that produces multiple alpha-emitting daughter isotopes, making it highly effective for the treatment of metastatic and resistant cancers.
Clionix offers dry nitrate Ac-225 and provides on-site labeling services for magistral (galenic) radiopharmaceutical production. Each labeling process is verified using Alpha Probe TLC analysis, ensuring the safe release and clinical use of the final product.
| Specification | Details |
|---|---|
| Isotope | Actinium-225 (Ac-225) |
| Origin | Oak Ridge National Laboratory (ORNL), USA |
| Chemical Form | Dry Nitrate |
| Half-life | ~10 days |
| Decay Mode | Alpha decay to Francium-221 |
| Decay Series | Neptunium-237 decay chain |
| Radiochemical Purity | ≥ 99.9% |
| Specific Activity | High (carrier-free) |
| Labeling Service | Available on-site or at your facility |
| QC Method | Alpha Probe TLC analysis for batch release |
| Certification | GMP-standard production and testing |
| Applications | Targeted Alpha Therapy (TAT) |
Targeted Alpha Therapy (TAT) for precision oncology.
Development of Ac-225-labeled radiopharmaceuticals for: Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Leukemia
Suitable for both clinical research and compassionate use programs